申联生物联营公司世之源获艾滋病单抗发明专利

Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), has recently obtained a patent from the National Intellectual Property Administration for an invention related to the treatment and functional cure of HIV infection using monoclonal antibodies targeting CD4 [1] Group 1 - The patent covers a method for preventing, treating, and functionally curing HIV infection through monoclonal antibodies and their compositions [1] - The drug UB-421, which is in the research pipeline for AIDS treatment, has a novel mechanism of action by competitively inhibiting HIV entry into host cells through binding to the CD4 receptor on T cells [1] - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing AIDS treatments, as it does not directly target viral genes and also possesses immunomodulatory effects [1] Group 2 - The research on UB-421 will primarily focus on areas such as multidrug resistance and functional cure in the domestic market [1]